NEWSLETTER
Zvekubvunza nezve zvigadzirwa zvedu kana mutengo runyorwa, ndapota siya email yako kwatiri uye isu tichabatana mukati memaawa makumi maviri nemana.
KUBVUNZA ZVINOMamiriro ekufambisa & inokurudzirwa nzira yekutumira:
nemhepo, negungwa kana nekutaura
Mamiriro ekuchengetedza:
Yakavharwa pakaoma, Room Temperature
Minimum Order Qty:
Kukurukurirana
Certification:
COA, HPLC, GC, HNMR, Assay, Mvura Yemukati(KF), TLC iripo
(S)-ethyl 2-(tert-butoxycarbonylaMino)-3-(4-nitrophenyl)propanoate;
Boc-(4-NO2)-L-Phe-OEt;
Boc-(4-NO2)-Oet;
Boc-Phe(4-NO2)-Oet;
L-Phenylalanine;
N- [(1,1-dimethylethoxy) carbonyl] -4-nitro-, ethyl ester
Vanowanzo shandiswa kutakura hupfu.Uye vanogona kudzivirira kupenya kwezuva nemvura kuti zvisashata.
Iyo hard carton inogona kuchengetedza zvigadzirwa zvako kubva pakuputsika uye kunyorova.
Nidanib, ikemikari.Zita remakemikari 1 h - indole - 6 - carboxylic acid, 2, 3 - dihydro - 3 - [[[4 - (methyl [(4 - methyl - 1 - piperazine) acetyl] amino] phenyl] amino]ne heartland yemethyl] - 2 - oxygen -, methyl ester, (z) - Clinically, chigadzirwa ichi chinoshandiswa kurapa idiopathic pulmonary fibrosis (IPF).
Nidanib akadzidza 1,529 varwere vane idiopathic pulmonary fibrosis (IPF) mumakiriniki akawanda miedzo.Iyo data yekuchengetedza yakapihwa yakavakirwa pakuenzanisa kwevarwere ve1061 vakapihwa nidanib 150 mg kaviri zuva nezuva uye placebo mune maviri 52-vhiki chikamu 3, randomized, double-blind, placebo-controlled controlled studies (INPULSIS-1 uye INPULSIS-2).Zviitiko zvinowanzoitika zvakashata zvinosanganiswa nekushandiswa kwenidanib zvaisanganisira manyoka, kushungurudza uye kurutsa, kurwadziwa kwepamuviri, kurasikirwa kwechido, kuora muviri, uye kukwidziridzwa kwechiropa enzymes.Ndokumbira utarise kune [Kungwarira] kune manejimendi einoenderana yakashata maitiro.Iyo Systematic Organ Classification (SOC) yeMedDRA inopa pfupiso yeakaipa maitiro uye frequency kurongedza.
Nidanib isubstrate yeP-gp (ona Pharmacokinetics).Muchidzidzo chakananga chekubatana kwezvinodhaka, kusanganiswa kwekutonga kwe ketoconazole, P-gp inhibitor ine simba, yakawedzera kuratidzwa kune nidanib kusvika ku1.61 nguva nenzvimbo iri pasi pe curve (AUC) uye 1.83 nguva nepamusoro-soro (Cmax).
Muchidzidzo chekudyidzana kwezvinodhaka neine simba P-gp inducer rifampicin, kuratidzwa nidanib kwakadzikira kusvika pa50.3%, sekuyerwa nenharaunda iri pasi pe curve (AUC), kana yasanganiswa ne rifampicin zvichienzaniswa neNidanib chete.Ne peak concentration (Cmax), yakadzikira kusvika 60.3%.
Kana ichishandiswa pamwe chete nechigadzirwa ichi, P-gp inhibitors ine simba (eg, ketoconazole kana erythromycin) inogona kuwedzera kuonekwa kune nidanib.Muzviitiko izvi, kushivirira kwemurwere kune nidanib kunofanira kunyatsoongororwa.Kutonga kwemaitiro akashata kungada kuregedzwa, kuderedzwa kwedosing, kana kurega kurapwa nechigadzirwa ichi (ona [Kushandiswa uye chipimo]).
P-gp potent inducers (semuenzaniso, rifampicin, carbamazepine, phenytoin uye St. John's wort) inogona kuderedza kuratidzwa kwe nidanib.Alternative masanganiswa asina kana kushoma P-gp induction inofanirwa kutariswa.
Gly-Phe | Boc-Phe-Gly-Ome | HN-Me-L-Phe.Hcl | Boc-D-Phe-D-Phe |
Boc-D-4-Chloropheny(alanine) | Fmoc-L-Phe-OH | L-Phe-NH2.Hcl | Boc-Phe-Gly |
L-Ala-Phe-OH | Fmoc-D-Phe-OH | 4-NO2-Phe-Oet | Boc-L-Phe-Onp |
Boc-Ala-Phe-OH | Fmoc-N-Me-L-Phe-OH | 4-NO2-Phe-Oet.HCl | Boc-L-Phe-Oet |
Boc-Ala-Phe-OH | FMOC-N-Me-D-Phe-OH | HD-Phe-OMe·HCl | Boc-4-NO2-D-Phe-OEt |
Fmoc-β-Ala-D-phe | Fmoc-Phe-Cl | HL-Phe-OMe.HCl | Boc-D,L-Phe(4-NO2)-OH |
Leu-Phe.Hcl | Fmoc-Phe(4-NO2)-OH | H-DL-Phe-OBzl .tos | Fmoc-Phe-Phe-OH |
Boc-Leu-Phe | Cbz-L-Phe-OH | H-DL-Phe(4-NO2)-OH.H2O | Fmoc-Phe-Gly-OH |
Cbz-L-Phe-Leu-OH | Cbz-D-Phe-OH | HL-Phe-OBzl.HCl | Fmoc-D-Phe(4-NO2)-OH |
L-Phe | Cbz-DL-Phe-OH | HL-Phe-OEt.HCl | Cbz-Phe-Arg-OH |
HD-Phe-OH | Cbz-D-Phe-OL | L-Phe-NH2 | Cbz-Phe-Ala-OH |
L-Phe-NCA | ZN-Me-L-Phe-OH | D-Phe-NH2 | Cbz-Phe-Gly-OH |
Tos-Phe | cbz-L-Phe-OSU | N-Ac-L-Phe-OH | Cbz-Phe-Met-OH |
L-Phe-ol | Phe-Ala | N-AC-L-Phe-Ome | Cbz-Phe-Gly-Oet |
L-Phe (4-NO2)-OH | L-Phe-Phe | N-Pht-Phe-OH | Boc-Phe-Gly-Gly-OH |
L-Phe (4-NO2).H2O | L-Phe-Trp | Boc-Phe-OH | Fmoc-L-Thr(tBu)-Phe-OH |
D-Phe(4-NO2)-OH.h2o | L-Phe-Leu-OH | Boc-D-Phe-OH | D-Phe-NH2 |
D-Phe(4-NO2)-OH | L-Phe-Tyr-OH | Boc-DL-Phe-OH | Tyr-Phe |
N-Me-D-Phe | L-Phe-Gly | BOC-N-Me-D-Phe-OH | DL-Phe-Ome.Hcl |
HN-Me-L-Phe-OH | D-Phe-D-Phe | Boc-N-Me-DL-Phe-OH | Boc-Met-Leu-Phe |
L-Phe.hcl | L-Phe-OBzl-OH | Boc-N-Me-L-Phe-OH | Asp-Phe-Ome |
4-NO2-D-phe.hcl | D-Phe-Obzl.Tos | Boc-N-Me-L-Phe-OH.DCHA | L-Homophe-OH |
HL-Phe-OtBu.HCl | Boc-Phe-Ala-OH | Boc-DN-Me-Phe•DCHA | D-Homophe-OH |
HD-Phe-OtBu.HCl | Boc-Phe-Leu-OH | Boc-Phe-Ol | L-Homophe-Oet.Hcl |
D,L-Phe-OtBu HCl | Boc-Phe-Trp-OH | Boc-D-Phe-Ol | D-Homophe-Oet.HCl |
HD-Phe(4-NO2)-Ome.HCl | Boc-L-Phe-Tyr-OH | Boc-Phe-NH2 | Boc-L-Homophe-OH |
D-Phe-Obzl.Hcl | Boc-Phe-Phe-OH | Boc-L-Phe-Ome | Boc-D-Homophe-OH |
DL-Phe-Ome.Hcl | Boc-D-Phe-Phe | Boc-D-Phe-Ome | Fmoc-L-HomoPhe-OH |
Boc-D-Phe(4-NO2)-OH | Cbz-D-Homophe-OH | Boc-Phe-Obzl | Fmoc-D-Homophe-OH |
Boc-L-Phe-OSU | Boc-Homophe-Leu-Phe-Ome | Boc-4-NO2-Phe-OH | Cbz-L-Homophe-OH |
Boc-D-Phe-OSU |
1. R&D sevhisi iripo
2. ISO yakasimbiswa mugadziri, vimbiso yehutano
3.Nzira yakazara yebasa rekutevera panguva yekugadzirwa
4.Kudhura kwakanyanya
5.Quality certification magwaro anopiwa pane chikumbiro chemutengi
6.Great after-sales service, kuchengetedza ukama hwepedyo nemutengi
7.Full resource kubatsira kuderedza mari yekutumira
8.Free sampuli yakapihwa kuti utarise kunaka kusati kwabhadharwa
9.Payment term yakataurirana
10.Assit vatengi vanobata nenyaya muChina